Terminal · Institutions

Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.

Atle Fund Management AB 13F Holdings -- Portfolio & Top Positions (2026-03-31)

Atle Fund Management AB (CIK 1381843) reported $309.7M across 39 reported positions in its SEC 13F filing for 2026-03-31. Largest positions: LLY ($26.8M, 8.67%), MRK ($22.9M, 7.40%), TMO ($14.4M, 4.67%), ONC ($12.1M, 3.92%), JNJ ($11.9M, 3.86%). Source: SEC Form 13F.

RankTickerCompanyValue% PortfolioSharesAction
1LLYELI LILLY & CO$26.8M8.67%39,722Added
2MRKMERCK & CO. INC$22.9M7.40%33,853Trimmed
3TMOTHERMO FISHER SCIENTIFIC CORP$14.4M4.67%22,986Trimmed
4ONCBEONE MEDICINES LTD-ADR$12.1M3.92%41,717Added
5JNJJOHNSON & JOHNSON$11.9M3.86%92,377New
6BBIOBRIDGEBIO PHARMA INC$11.9M3.84%111,363Trimmed
7VRTXVERTEX PHARMACEUTICALS INC$11.2M3.61%22,984Hold
8ABBVABBVIE INC$10.4M3.35%108,181Hold
9SYKSTRYKER CORPORATION$9.6M3.09%26,835Hold
10ISRGINTUITIVE SURGICAL INC$9.4M3.05%70,851Added
11IONSIONIS PHARMACEUTICALS INC$9.4M3.03%27,873Trimmed
12MIRMMIRUM PHARMACEUTICALS INC$9.4M3.03%195,768Added
13CVSCVS HEALTH CORP$9.3M2.99%23,773Trimmed
14RVMDREVOLUTION MEDICINES INC$9.1M2.93%617,245Added
15BSXBOSTON SCIENTIFIC CORP$8.8M2.86%40,432Trimmed
16AMGNAMGEN INC$8.7M2.81%21,903Hold
17EWEDWARDS LIFESCIENCES CORP$8.3M2.67%106,518New
18ALKSALKERMES PLC$8.2M2.66%242,473Hold
19INCYINCYTE CORP$8.0M2.57%50,796Trimmed
20NBIXNEUROCRINE BIOSCIENCES INC$7.9M2.54%89,685Trimmed
21GILDGILEAD SCIENCES INC$7.2M2.31%47,967Trimmed
22KRYSKRYSTAL BIOTECH, INC$6.8M2.19%37,579Added
23ABCCENCORA INC$6.6M2.13%23,470Trimmed
24IRTCIRHYTHM TECHNOLOGIES INC$6.3M2.02%22,322Trimmed
25INSMINSMED INC$6.0M1.92%97,438Added

Source: SEC Form 13F filings · as of 2026-03-31